Balaxi Pharmaceuticals Ltd
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]
- Market Cap ₹ 537 Cr.
- Current Price ₹ 97.2
- High / Low ₹ 151 / 80.0
- Stock P/E 14.3
- Book Value ₹ 36.3
- Dividend Yield 0.00 %
- ROCE 21.4 %
- ROE -26.9 %
- Face Value ₹ 2.00
Pros
Cons
- Promoter holding has decreased over last quarter: -0.37%
- Company has a low return on equity of 10.5% over last 3 years.
- Debtor days have increased from 59.0 to 84.3 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
14 | 46 | 231 | 279 | 336 | 241 | 241 | |
12 | 37 | 189 | 229 | 279 | 197 | 193 | |
Operating Profit | 2 | 8 | 43 | 51 | 57 | 45 | 48 |
OPM % | 11% | 18% | 18% | 18% | 17% | 18% | 20% |
1 | 1 | 2 | 5 | 3 | -38 | 5 | |
Interest | 0 | 0 | 0 | 1 | 1 | 3 | 2 |
Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
Profit before tax | 2 | 9 | 44 | 55 | 57 | 2 | 49 |
Tax % | 19% | 31% | 14% | 13% | 19% | 219% | |
2 | 6 | 38 | 48 | 46 | -2 | 45 | |
EPS in Rs | 1.30 | 1.22 | 7.63 | 9.53 | 9.03 | -0.44 | 8.65 |
Dividend Payout % | 0% | 0% | 0% | 1% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 78% |
3 Years: | 1% |
TTM: | -25% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 7% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 43% |
3 Years: | -7% |
1 Year: | 10% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 18% |
3 Years: | 11% |
Last Year: | -27% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Equity Capital | 3 | 10 | 10 | 10 | 10 | 11 |
Reserves | 0 | 18 | 55 | 103 | 162 | 187 |
0 | 0 | 4 | 4 | 13 | 19 | |
3 | 8 | 31 | 60 | 54 | 41 | |
Total Liabilities | 6 | 36 | 100 | 176 | 240 | 258 |
0 | 0 | 2 | 29 | 41 | 41 | |
CWIP | 0 | 0 | 0 | 1 | 3 | 2 |
Investments | 0 | 0 | 3 | 0 | 0 | 0 |
6 | 36 | 94 | 147 | 195 | 215 | |
Total Assets | 6 | 36 | 100 | 176 | 240 | 258 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
-2 | -14 | 0 | 34 | 6 | 5 | |
-0 | -0 | -6 | -28 | -11 | -1 | |
0 | 18 | 4 | -0 | 26 | 30 | |
Net Cash Flow | -2 | 4 | -2 | 6 | 21 | 34 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 147 | 238 | 121 | 36 | 57 | 84 |
Inventory Days | 9 | 29 | 184 | 189 | 233 | |
Days Payable | 64 | 53 | 92 | 62 | 82 | |
Cash Conversion Cycle | 147 | 183 | 97 | 129 | 184 | 235 |
Working Capital Days | 82 | 181 | 96 | 97 | 133 | 168 |
ROCE % | 57% | 93% | 60% | 39% | 21% |
Documents
Announcements
-
Copy of Newspaper Publication
8 October 2024 - BALAXI PHARMACEUTICALS LIMITED has informed about Copy of Newspaper Publication
-
Notice Of Shareholders Meetings-XBRL
7 October 2024 - BALAXI PHARMACEUTICALS LIMITED has informed about Notice of Shareholders Meeting for Postal Ballot
-
Shareholders meeting
7 October 2024 - BALAXI PHARMACEUTICALS LIMITED has informed regarding Notice of Postal Ballot
-
Trading Window-XBRL
27 September 2024 - BALAXI PHARMACEUTICALS LIMITED has informed about Closure of Trading Window
-
Trading Window
27 September 2024 - BALAXI PHARMACEUTICALS LIMITED has informed regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Annual reports
Concalls
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022TranscriptPPT
-
Nov 2022Transcript PPT
-
Oct 2022TranscriptNotesPPT
-
Aug 2022TranscriptPPT
-
Aug 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022TranscriptNotesPPT
-
Jun 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Jul 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Oct 2020TranscriptNotesPPT
Product Portfolio
Balaxi Pharmaceuticals Limited has a rich portfolio of 610 pharmaceutical product registrations. The pharma product portfolio of the company includes Tablets (46%), Injectables(17%), Liquids (12%), Capsules (13%), and Others (12%). The pharma products are sourced from WHO-GMP certified contract manufacturers based in India, China, and Portugal. [1] [2] [3]